Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.58 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4613525 | 0.83 | CYP2A6 (0.47) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL7300809 | 0.82 | CYP2A6 (0.45) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL27989815 | 0.81 | CYP2A6 (0.74) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL2125063 | 0.81 | CYP2A6 (0.72) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL21295827 | 0.78 | PTPRC (0.36) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL3997707 | 0.76 | — | — | |
| SCHEMBL196583 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL149952 | 0.74 | CYP2A6 (1.00) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL5924659 | 0.73 | CYP2A6 (0.56) | CYP2A6CYP2B6CYP2E1KCNH2CYP17A1 | |
| SCHEMBL276590 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| CN-105694582-A | Photocuring solder-resist ink | 北京英力科技发展有限公司 | 2016-06-22 | — | — | CN | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | claimed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | claimed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | claimed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | claimed |
| US-5831115-A | CYCLOBUTANECARBOXAMIDES | ABBOTT LABORATORIES (US) | 1998-11-03 | — | — | US | claimed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0821665-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | claimed |
| EP-0728145-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | Ciba-Geigy Japan Limited (JP) | 1996-08-28 | — | — | EP | claimed |
| EP-0674635-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-10-04 | — | — | EP | claimed |
| WO-1995012611-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | JAPAT LTD. (CH) | 1995-05-11 | — | — | WO | claimed |
| WO-1994014803-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-07-07 | — | — | WO | claimed |
| CN-1065070-A | 11 beta-aryl-4-estrenes of 6,7-sex change | SCHERING AG (DE) | 1992-10-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | CYP2A6 905/4885CYP2B6 801/4885CYP2E1 265/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP2A6 215/4885CYP2B6 452/4885CYP2E1 684/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | CYP2A6 43/4885CYP2B6 67/4885CYP2E1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.